Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on invested capital (ROIC) high or low?
The return on invested capital (ROIC) of 29.53% is 67% below its 5-year average of 88.96%, near the low end of its 5-year range (29.53%–318.06%).
As of the fiscal period ended Wednesday, December 31, 2025. 13.81% below its 12-month average of 34.26%.
Annual fiscal-year return on invested capital; no daily interpolation.
RETURN ON INVESTED CAPITAL (ROIC)
29.53%
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
34.26%
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
43.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
88.96%
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
112.03%
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
52.69%
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
44.41%
CURRENT VS TTM AVG
-13.81%
CURRENT VS 3Y AVG
-31.37%
CURRENT VS 5Y AVG
-66.81%
CURRENT VS 10Y AVG
-73.64%
CURRENT VS 15Y AVG
-43.95%
CURRENT VS 20Y AVG
-33.51%
SECTOR MEDIAN · HEALTHCARE
8.53%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
+246.19%
vs the sector median at left
Novo Nordisk A/S
Market Cap
$209.19B
Return on Invested Capital (ROIC)
29.53%
TTM Avg
34.26%
3Y Avg
43.03%
5Y Avg
88.96%
Market Cap
$207.87B
Return on Invested Capital (ROIC)
13.16%
TTM Avg
11.04%
3Y Avg
11.80%
5Y Avg
12.80%
Market Cap
$213.42B
Return on Invested Capital (ROIC)
7.58%
TTM Avg
7.80%
3Y Avg
8.16%
5Y Avg
9.10%
Market Cap
$184.11B
Return on Invested Capital (ROIC)
8.43%
TTM Avg
9.16%
3Y Avg
9.70%
5Y Avg
9.86%
Market Cap
$161.66B
Return on Invested Capital (ROIC)
21.53%
TTM Avg
11.95%
3Y Avg
11.58%
5Y Avg
9.92%
Market Cap
$142.54B
Return on Invested Capital (ROIC)
8.84%
TTM Avg
9.06%
3Y Avg
10.60%
5Y Avg
10.43%
Market Cap
$137.13B
Return on Invested Capital (ROIC)
5.72%
TTM Avg
5.90%
3Y Avg
6.54%
5Y Avg
6.70%
Market Cap
$133.37B
Return on Invested Capital (ROIC)
13.90%
TTM Avg
13.75%
3Y Avg
11.92%
5Y Avg
10.17%
Market Cap
$133.25B
Return on Invested Capital (ROIC)
4.72%
TTM Avg
4.17%
3Y Avg
4.46%
5Y Avg
4.93%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $209.19B | 29.53% | 34.26% | 43.03% | 88.96% |
| Amgen Inc. (AMGN)vs › | $207.87B | 13.16% | 11.04% | 11.80% | 12.80% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $213.42B | 7.58% | 7.80% | 8.16% | 9.10% |
| Abbott Laboratories (ABT)vs › | $184.11B | 8.43% | 9.16% | 9.70% | 9.86% |
| Gilead Sciences, Inc. (GILD)vs › | $161.66B | 21.53% | 11.95% | 11.58% | 9.92% |
| Pfizer Inc. (PFE)vs › | $142.54B | 8.84% | 9.06% | 10.60% | 10.43% |
| Danaher Corporation (DHR)vs › | $137.13B | 5.72% | 5.90% | 6.54% | 6.70% |
| Bristol-Myers Squibb Company (BMY)vs › | $133.37B | 13.90% | 13.75% | 11.92% | 10.17% |
| CVS Health Corp. (CVS)vs › | $133.25B | 4.72% | 4.17% | 4.46% | 4.93% |
| AstraZeneca PLC (AZN)vs › | $131.47B | 13.03% | 11.66% | 9.40% | 7.60% |
ROIC
29.5%
ROE
60.7%
ROIC = NOPAT / Invested Capital
Return on invested capital measures the after-tax return a company earns on all capital (debt and equity) invested in the business.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-12-31 | 29.53% |
| 2024-12-31 | 38.99% |
| 2023-12-31 | 54.20% |
| 2022-12-31 | 49.39% |
| 2021-12-31 | 43.62% |
| 2020-12-31 | 318.06% |
| 2019-12-31 | 411.56% |
| 2018-12-31 | 67.10% |
| 2017-12-31 | 67.30% |
| 2016-12-31 | 76.35% |
| 2015-12-31 | 76.23% |
| 2014-12-31 | 60.75% |
| 2013-12-31 | 50.44% |
| 2012-12-31 | 51.01% |
| 2011-12-31 | 39.41% |
| 2010-12-31 | 33.33% |
| 2009-12-31 | 27.54% |
| 2008-12-31 | 24.11% |
| 2007-12-31 | 18.52% |
| 2006-12-31 | 18.41% |
| 2005-12-31 | 17.55% |
| 2004-12-31 | 15.31% |
| 2003-12-31 | 14.80% |
| 2002-12-31 | 14.90% |
| 2001-12-31 | 15.14% |
| 2000-12-31 | 14.23% |
| 1999-12-31 | 6.80% |
| 1998-12-31 | 4.00% |
| 1997-12-31 | 7.52% |
| 1996-12-31 | 8.07% |
